A5006524407- Inflammatory Bowel Disease
- Microscopic Colitis
- Eosinophilic Esophagitis
- Spondyloarthritis Studies and Treatments
- Rheumatoid Arthritis Research and Therapies
- Adolescent and Pediatric Healthcare
- Psoriasis: Treatment and Pathogenesis
- Celiac Disease Research and Management
- Autoimmune and Inflammatory Disorders Research
- Gastrointestinal motility and disorders
- Pharmaceutical studies and practices
- Biosimilars and Bioanalytical Methods
- Helicobacter pylori-related gastroenterology studies
- Diabetes Treatment and Management
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Diverticular Disease and Complications
- Colorectal Cancer Treatments and Studies
- Pharmacology and Obesity Treatment
- CAR-T cell therapy research
- Autoimmune and Inflammatory Disorders
- Diet and metabolism studies
- Clostridium difficile and Clostridium perfringens research
- Health Systems, Economic Evaluations, Quality of Life
- Cancer Immunotherapy and Biomarkers
- Pregnancy and Medication Impact
Eli Lilly (United States)
2016-2025
Eli Lilly (Spain)
2025
Walden University
2024
University of Mississippi Medical Center
2024
Louisiana State University Health Sciences Center New Orleans
2024
C. S. Mott Children's Hospital
2024
University of Michigan
2024
Indianapolis Zoo
2024
Wilmington University
2024
Indiana University Bloomington
2014-2016
Mirikizumab, a p19-directed interleukin-23 monoclonal antibody, is efficacious in inducing clinical remission at week 12 (W12) and maintaining W52 patients with moderately to severely active ulcerative colitis. Results are presented from the open-label extension study through W104.
Abstract Background Mirikizumab (miri) is a selective IL23p19 monoclonal antibody approved for the treatment of ulcerative colitis. The primary focus VIVID-1 trial (NCT03926130) was to demonstrate efficacy and safety mirikizumab compared placebo (PBO) in patients (pts) with moderate-to-severe Crohn’s disease. Here we present miri up Week 52 (W52) from Phase 3, randomised, double-blind, double-dummy, active- PBO-controlled, treat-through study. Methods Adult pts (N=1065) were randomized 6:3:2...
Abstract Aims We assessed changes in body composition following tirzepatide treatment a substudy of participants with obesity or overweight from the SURMOUNT‐1 trial, overall and post hoc clinically relevant subgroups. Materials Methods Substudy ( n = 160 2539 SURMOUNT‐1) underwent dual‐energy X‐ray absorptiometry (DXA) at baseline Week 72. Body parameters were evaluated by analysis covariance, logistic regression Fisher's exact test. Post subgroup analyses conducted sex (female male), age...
Abstract Background Patient-reported outcomes (PROs) are increasingly used to track symptoms and assess disease activity, quality of life, treatment effectiveness. It is therefore important understand which PROs patients with rheumatic musculoskeletal consider most for management. Methods Adult US within the ArthritisPower registry ankylosing spondylitis, fibromyalgia syndrome, osteoarthritis, osteoporosis, psoriatic arthritis, rheumatoid systemic lupus erythematosus were invited select...
Abstract Background The Communicating Needs and Features of IBD Experiences (CONFIDE) study aimed to evaluate the experience impact ulcerative colitis (UC) symptoms on patients’ lives elucidate gaps in communication between patients health care professionals (HCPs). Methods Online, quantitative, cross-sectional surveys with moderate-to-severe UC HCPs responsible for making prescribing decisions were conducted United States (US) Europe. disease severity was defined by treatment, steroid use,...
Efficacy and safety of mirikizumab, a p19-targeted anti-interleukin-23 monoclonal antibody, for moderately to severely active ulcerative colitis was demonstrated previously. We evaluated clinical response, baseline characteristics, status in patients not responding by 12 weeks (W) induction who then received extended treatment.
Introduction Treatment goals for ulcerative colitis (UC) are evolving from the achievement of clinical remission to more rigorous defined by endoscopic and histologic healing. Achievement deeper targets aims reduce risk colectomy, hospitalizations, colorectal cancer.
The early post-partum period is a crucial time for breastfeeding support. Mothers who have physical and emotional support during this are more likely to be successful in breastfeeding. This study examined the relationship between father involvement breast feeding initiation duration first-time mothers.Overall, 146 women attended childbirth education class or course at BABS were asked fill out Childbirth Experiences Survey, which explored key topics such as (1) initiation, (2) breastfeeding,...
Abstract Background and Aims Ulcerative colitis [UC], a chronic inflammatory bowel disease, may manifest with symptoms of increased stool frequency [SF], rectal bleeding [RB], urgency [BU], abdominal pain [AP], fatigue. Mirikizumab, an anti-IL-23p19 antibody, demonstrated efficacy safety in patients moderately to severely active UC the LUCENT Phase 3 trials. We evaluated mirikizumab’s achieving symptom control time improvement during induction, maintenance sustained control, 'comprehensive...
Abstract Background Crohn’s disease (CD) and Ulcerative colitis (UC) affect patients’ physical emotional well-being, posing substantial challenges to daily functioning.1 The CONFIDE study explored perspectives on the experiences impact of CD UC-related symptoms in US, Europe (France, Germany, Italy, Spain, UK), Japan. Here, we assessed moderate-to-severe or UC self-reported health status using EQ-5D-5L questionnaire. Methods Online, quantitative, cross-sectional surveys were conducted among...
Abstract Background Improving health-related quality of life (HRQoL) is a long-term treatment goal for Crohn’s disease (CD) and Ulcerative colitis (UC).1 The CONFIDE study explored patients’ perspectives on the experiences impact CD UC-related symptoms in US, Europe (France, Germany, Italy, Spain, UK), Japan. Here, we assessed HRQoL among patients with or UC using Short Inflammatory Bowel Disease Questionnaire (SIBDQ). Methods Online, quantitative, cross-sectional surveys were conducted...
Abstract Aims To understand real‐world tirzepatide utilization and effectiveness (change in weight body mass index [BMI]) among people without type 2 diabetes (T2D) the United States. Materials Methods This retrospective, observational study used Optum's de‐identified Market Clarity database (index date: first‐observed claim; period: 13 May 2022–30 September 2023). Outcomes were assessed 3 cohorts: (1) Overall cohort: age ≥18 years; ≥1 no baseline T2D diagnosis codes, anti‐diabetes...
The global Communicating Needs and Features of Inflammatory Bowel Disease Experiences (CONFIDE) study aimed to evaluate the impact ulcerative colitis (UC)- Crohn's disease (CD)-related symptoms on patients' lives elucidate communication gaps between patients health care professionals (HCPs). We report findings from in with UC or CD HCPs Japan. Online, quantitative, cross-sectional surveys were conducted Japan for moderate-to-severe responsible and/or CD. Subgroup analyses based activity...
Abstract BACKGROUND Disease control is an important treatment goal for Crohn’s disease (CD) and ulcerative colitis (UC). The Communicating Needs Features of Inflammatory bowel (IBD) Experiences (CONFIDE) study explored patient healthcare professional perspectives on the experiences impact CD UC-related symptoms patients in United States (US), Europe (France, Germany, Italy, Spain, UK), Japan. Here, we perceptions among with or UC using validated IBD-Control questionnaire. METHODS Online,...
Abstract INTRODUCTION Abdominal pain (AP) is the most common symptom in patients with Crohn’s disease (CD) and negatively impacts quality of life. We qualitatively examined changes AP among participants moderately to severely active CD who completed phase 3, randomized, double-blind, placebo- active-controlled mirikizumab clinical trial (NCT03926130). METHODS Web-assisted, semi-structured exit interviews were conducted 62 from either mirikizumab, ustekinumab, or placebo arms. Interviews...
Abstract BACKGROUND Bowel urgency (BU) is a disruptive symptom for patients with Crohn’s disease (CD) and affects their quality of life. This study used data from the Communicating Needs Features IBD Experiences (CONFIDE) survey to explore patient healthcare professional (HCP) perceptions broad impact BU on patients’ emotions daily lives. METHODS Online, quantitative, cross-sectional surveys were conducted in moderate-to-severe CD gastroenterology HCPs US, Europe (France, Germany, Italy,...
To understand treatment patterns and effectiveness of tirzepatide among people without type 2 diabetes (T2D) in the US. This retrospective, observational, descriptive study used Healthcare Integrated Research Database (index date: first-observed claim; index period: May 13, 2022-May 24, 2023). Key eligibility criteria were: age ≥ 18 years; 1 no T2D diagnosis codes or glycated hemoglobin 6.5%, anti-diabetes medications (except metformin); continuous medical/pharmacy enrollment for 12 months...
Abstract Aims To understand real‐world tirzepatide use among individuals without type 2 diabetes ( T2D ) diagnoses in a US electronic health record EHR database. Materials and Methods This retrospective, descriptive, cohort study used Veradigm's® Network database linked with administrative claims. Adults (≥18 years) included had ≥1 prescription (index period: 13 May 2022–31 August 2023); continuous medical pharmacy enrolment for ≥12 months pre‐index; no diagnosis or baseline medications...